Table 3.
Response to neo-adjuvant chemotherapy.
| Major responses | Minor responses | No response | Not evaluable Not available | Not given chemotherapy | Total | |
|---|---|---|---|---|---|---|
| Synovial sarcoma | 38 (8 CR) | 18 | 39 | 9 | 3 | 107 |
| MPNST non-NFl | 16 (3 CR) | 9 | 16 | 2 | 1 | 44 |
| MPNST in NF1 | 2 | 23 | 2 | 27 | ||
| Alveolar soft part sarcoma | 3 (2 CR) | 1 | 5 | 1 | 10 | |
| Angiosarcoma | 2 | 1 | 3 | |||
| Clear cell sarcoma | 1 | 1 | 3 | 5 | ||
| Epithelioid sarcoma | 2 (1 CR) | – | 5 | 7 | ||
| Fibrosarcoma | 3 | 2 | 3 | 2 | 10 | |
| Haemangiopericytoma | 5 | 1 | 2 | 1 | 9 | |
| Leiomyosarcoma | 4 (2 CR) | – | 5 | 9 | ||
| Liposarcoma | 1 | 1 | 2 | 1 | 5 | |
| MPH | 4 (1 CR) | – | 2 | 1 | 7 | |
| Spindle cell NOS | 34 (8 CR) | 10 | 14 | 2 | 1 | 61 |
| Total | 115 (25 CR) | 44 | 119 | 17 | 9 | 304 |
MPNST, malignant peripheral nerve sheath tumour; NF1, neurofibromatosis type 1; MFH, malignant fibrous histiocytoma; NOS, not otherwise specified.
Chemotherapy administered
Vincristine, actinomycinD, cyclophosphamide (VAC) - 17 patients.
Vincristine, actinomycinD, cyclophosphamide, doxorubicin (VACA) - 41.
Vincristine, actinomycinD, cyclophosphamide, dacarbazine - 17.
Ifosfamide, vincristine, actinomycinD (IVA) - 100.
Vincristine, actinomycinD, ifosfamide, doxorubicin (VAIA) - 50.
Ifosfamide and doxorubicin (±vincristine) - 51.
Carboplatin, etoposide, vincristine, actinomycinD, ifosfamide, epirubicin (CEVAIE) - 26.
Carboplatin, etoposide - 4.
Carboplatin, etoposide, ifosfamide - 1.